




Merck
PCSK9 inhibitor
 oral macrocyclic peptide inhibitor of PCSK9
 Ph. III for hypercholesterolemia
 from mRNA display + SBDD
 MK-0616
 MERCK, RAHWAY, NJ




Kymera/Sanofi
IRAK4 degrader
 oral IRAK4 degrader
 Ph. II in AD and HS
 from SBDD of ligands for CRBN, IRAK4, and linker
 KT-474
 KYMERA THERAPEUTICS, MA / SANOFI, NJ




Vertex
NaV1.8 inhibitor
 oral NaV1.8 selective inhibitor
 Ph. III for acute pain
 discovery undisclosed
 suzetrigine (VX-548)
 VERTEX PHARMACEUTICALS, SAN DIEGO, CA




Revolution Medicines
KRAS^{G12C} inhibitor
 oral KRAS^{G12C}(ON) tri-complex inhibitor
 Ph. I/II for adv. solid tumors
 from covalent tethering approach + SBDD
 RMC-6291
 REVOLUTION MEDICINES, REDWOOD CITY, CA




Relay
FGFR2 inhibitor
 oral covalent FGFR2 inhibitor
 Ph. II for cholangiocarcinoma
 from rational design with MD simulations
 lirafugratinib (RLY-4008)
 RELAY THERAPEUTICS, CAMBRIDGE, MA




Chugai/Lilly
GLP-1R agonist
 oral non-peptide GLP-1R agonist
 Ph. III for obesity + type 2 diabetes
 from LLC-PK1 cell HTS + opt
 orforglipron
 CHUGAI, SHIZUOKA, JP / ELI LILLY, IN




Roche/Madrigal
THR-β-selective agonist
 oral THR-β-selective agonist
 Ph. III for NASH
 opt. of triiodothyronine
 resmetirom
 ROCHE, NUTLEY, NJ / MADRIGAL, PA



Pfizer
JAK3/TEC-family inhibitor
 Oral JAK3/TEC-family kinase inhibitor
 approved for alopecia areata
 structure-based design from tofacitinib
 ritlecitinib (LITFULO®)
 PFIZER, GROTON, CT



Reata/Biogen
Nrf2 activator
 oral once-daily Nrf2 activator
 approved to treat Friedreich's ataxia
 from modification of oleanolic acid
 omaxeloxolone (SKYCLARYS®)
 REATA PHARMA, TX / BIOGEN, MA



Pfizer/Springworks
γ-secretase inhibitor
 oral γ-secretase inhibitor
 approved for desmoid tumors
 single-digit nanomolar potency for Aβ reduction in vitro
 nirogacestat (OGSIVEO®)
 PFIZER / SPRINGWORKS THERAPEUTICS